-50.5%
CPNG vs MRNA
-67.9%
+17.4%
-69.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.1% | +5.4% | -2.3% | +2.5% |
| 7D | -1.1% | -1.1% | 0.0% | -1.0% |
| 30D | -7.4% | +126.1% | -133.5% | -21.9% |
| 3M | -12.3% | +190.0% | -202.4% | -30.1% |
| 6M | -19.4% | +157.2% | -176.7% | -34.6% |
| YTD | -35.9% | +388.2% | -424.1% | -54.8% |
| 1Y | -53.4% | +467.0% | -520.4% | -68.6% |
| 3Y | -20.0% | +36.1% | -56.1% | -32.3% |
| All | -50.5% | -67.9% | +17.4% | -50.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling